Source: GlobalNewswire

Press Release: DalCor Pharmaceuticals : DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19

New dal-COVID Phase 2 proof of concept study results anticipated in Q1 2021 New dal-COVID Phase 2 proof of concept study results anticipated in Q1 2021

Read full article »
DalCor Pharmaceuticals's Competitors | DalCor Pharmaceuticals's News | DalCor Pharmaceuticals's Financials
Stay up-to-date with the latest news on DalCor
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Fouzia Laghrissi-Thode's photo - CEO of DalCor

CEO

Fouzia Laghrissi-Thode

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on DalCor